A cost-utility analysis of cervical cancer vaccination in preadolescent Canadian females (Q33514126)

27 July 2017

A cost-utility analysis of cervical cancer vaccination in preadolescent Canadian females (English)

1 reference

27 July 2017

cervix uterine cancer

1 reference

2

Chris T Bauch

1 reference

27 July 2017

Andrea M Anonychuk

1

1 reference

27 July 2017

Maraki Fikre Merid

series ordinal

3

1 reference

27 July 2017

Georges Van Kriekinge

series ordinal

4

1 reference

27 July 2017

Nadia Demarteau

series ordinal

5

1 reference

27 July 2017

language of work or name

English

0 references

publication date

31 October 2009

1 reference

27 July 2017

1 reference

27 July 2017

9

1 reference

27 July 2017

401

1 reference

Creative Commons Attribution 2.0 Generic

27 July 2017

start time

31 October 2009

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

1 reference

April 2022 Public Data File from Crossref

exact match

https://scigraph.springernature.com/pub.10.1186/1471-2458-9-401

0 references

cites work

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2777872

Comparison of detailed and succinct cohort modelling approaches in a multi-regional evaluation of cervical cancer vaccination

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2777872

Adding a quadrivalent human papillomavirus vaccine to the UK cervical cancer screening programme: A cost-effectiveness analysis

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2777872

Cost-effectiveness of human papillomavirus vaccination in the United States

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2777872

Human papilloma virus vaccine and cervical cancer screening acceptability among adults in Quebec, Canada

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2777872

The value of including boys in an HPV vaccination programme: a cost-effectiveness analysis in a low-resource setting

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2777872

Cost-effectiveness of HPV 16, 18 vaccination in Brazil

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2777872

Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2777872

Model for assessing human papillomavirus vaccination strategies

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2777872

Estimating the long-term impact of a prophylactic human papillomavirus 16/18 vaccine on the burden of cervical cancer in the UK

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2777872

Chapter 21: Modelling the impact of HPV vaccines on cervical cancer and screening programmes

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2777872

Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2777872

Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2777872

Immune responses to human papillomavirus

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2777872

Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2777872

Role of herd immunity in determining the effect of vaccines against sexually transmitted disease

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2777872

Valuing prevention through economic evaluation: some considerations regarding the choice of discount model for health effects with focus on infectious diseases

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2777872

Evaluating human papillomavirus vaccination programs

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2777872

Against which human papillomavirus types shall we vaccinate and screen? The international perspective

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2777872

Cost-effectiveness of a potential vaccine for human papillomavirus

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2777872

Economic evaluation of vaccination programmes: a consensus statement focusing on viral hepatitis

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2777872

Generation and neutralization of pseudovirions of human papillomavirus type 33.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2777872

Cervical human papillomavirus infection and intraepithelial neoplasia: a review

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2777872

The natural history of human papillomavirus type 16 capsid antibodies among a cohort of university women.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2777872

Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2777872

Human papillomavirus types 6 and 11 have antigenically distinct strongly immunogenic conformationally dependent neutralizing epitopes

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2777872

An epidemiological model with a delay and a nonlinear incidence rate.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2777872

Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial

14 July 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2458-9-401

A controlled trial of a human papillomavirus type 16 vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2458-9-401

Cost-effectiveness of quadrivalent human papillomavirus (HPV) vaccination in Mexico: a transmission dynamic model-based evaluation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2458-9-401

A cost-effectiveness analysis of adding a human papillomavirus vaccine to the Australian National Cervical Cancer Screening Program.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2458-9-401

Cost-utility of universal hepatitis A vaccination in Canada.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2458-9-401

Assessing the introduction of universal human papillomavirus vaccination for preadolescent girls in The Netherlands

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2458-9-401

Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2458-9-401

Utility scores for chronic conditions in a community-dwelling population

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2458-9-401

Projected Clinical Benefits and Cost-effectiveness of a Human Papillomavirus 16/18 Vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2458-9-401

Incorporating herd immunity effects into cohort models of vaccine cost-effectiveness

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2777872

Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: modeling of sustained antibody responses

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2777872

A monoclonal antibody against intact human papillomavirus type 16 capsids blocks the serological reactivity of most human sera

31 October 2018

1 reference

12 December 2020

The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada

1 reference

12 December 2020

Cost-effectiveness analysis of the introduction of a quadrivalent human papillomavirus vaccine in France

1 reference

12 December 2020

Economic evaluation of vaccination programs: the impact of herd-immunity

1 reference

12 December 2020

Cost-utility analysis of vaccination against HPV in Israel.

1 reference

12 December 2020

Economic analysis of HPV-vaccines: not so simple?

1 reference

12 December 2020

Statement on human papillomavirus vaccine. An Advisory Committee Statement (ACS)

1 reference

12 December 2020

Identifiers

DOI

10.1186/1471-2458-9-401

1 reference

Dimensions Publication ID

27 July 2017

1 reference

https://scigraph.springernature.com/pub.10.1186/1471-2458-9-401

9 September 2019

1 reference

27 July 2017

1 reference